Apoxis S.A., the Swiss biopharmaceutical company

APOXIS S.A.
18-20 Avenue de Sévelin
1004
Lausanne
1004 Lausanne
Auf Karte anzeigen
021 620 60 80
021 620 60 99
info@apoxis.com
www.apoxis.com
Firmenbeschrieb
Apoxis S.A. is a Swiss biopharmaceutical company developing innovative therapeutics for the treatment of cancer and autoimmune disorders. The company particularly focuses on diseases with unmet medical needs and high commercial potential.Marktleistungen
-
Apoptosis
Apoptosis, or programmed cell death, is a physiological process occurring during embryogenesis and adult life that results in the removal of superfluous, viral infected, transformed and damaged cells and, thereby, is key to organism homeostasis. During apoptosis, a series of events take place in which the cell actively participates in its own destruction. Programmed cell death can be triggered by a large variety of stimuli, such as engagement of cell surface death receptors, nutrient depletion, virus infection and DNA damage caused by UV irradiation or cancer drugs. The apoptotic program results in typical morphological changes, notably loss of plasma membrane asymmetry, cytoplasm compaction and multiple cleavage of nucleic acids.
-
At the end of this physiological process, the dying cells become fragmented into so-called “apoptotic bodies”, which are rapidly engulfed by phagocytic cells without eliciting an inflammatory response. Nevertheless, excessive apoptosis may initiate an inflammatory situation. In pathologies as varied as autoimmune hepatitis, graft-versus host disease and neurodegenerative diseases, uncontrolled apoptosis results in undesirable processes, such as recruitment of leukocytes, activation of macrophages and remodeling of tissues. For these reasons, it is believed that controlling apoptosis constitutes a unique opportunity to tackle diseases, for which more classical therapeutic approaches have thus far been unsuccessful.
-
The tumor necrosis factor family
Tumor necrosis factor (TNF) and the other twenty or so members of the TNF family (i.e. FasL, CD40L and EDA1) are transmembrane proteins, which, for many may be cleaved by metalloproteinases and thereby released as soluble proteins. Both cleaved and non-cleaved ligands spontaneously assemble into biologically active trimers.
-
TNF family proteins bind to corresponding receptors, of which there are approximately 30 members. Upon engagement by its ligand, the TNF receptor initiates signaling cascades leading to cellular processes as varied as proliferation, differentiation and apoptosis. The members of the TNF and of the TNF receptor families play critical functions in many important physiological processes, such as immunity, neural development and bone metabolism. Thus, it is not surprising that these proteins have a determining role in the course of numerous pathologies. This situation has prompted Apoxis to undertake the development of drug candidates derived from proteins belonging to the TNF and TNF receptor families aimed at the treatment of cancers and immune-related disorders.
Kernkompetenzen
-
Innovationskraft in der Entwicklung neuer Lösungen und Produkte
-
Qualitativ einzigartige Marktleistungen
-
Herausragend bezüglich Fachkompetenz und Beratung

